Clinical trials: Patients With Major Depressive Disorder
Depression
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued duloxetine in the treatment of patients with treatment resistant depression (TRD).
- Trial name
- NCT01309945
- Testing
- Duloxetine, BMS-820836
- Where
- 84 sites in United States, Canada and 4 more
- Volunteers
- 889 people
- Sponsor
- Bristol-Myers Squibb
Depression
Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.
Phase III long-term safety study of Effexor XR in patients with major depression.
- Trial name
- NCT00225524
- Testing
- Effexor XR
- Where
- 73 sites in Japan
- Volunteers
- 150 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depression
Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression
The purpose of this study is to investigate whether patients with depression should be offered vitamin D supplements, or it has no significance in relation to treatment outcomes.
- Trial name
- D3-vit-dep (NCT01390662)
- Testing
- Vitamin D3
- Where
- 3 sites in Denmark
- Volunteers
- 150 people
- Sponsor
- Region Syddanmark
Major Depressive Disorder (MDD)
A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder
The purpose of this study is to assess nausea severity in response to four different drug dosing strategies of Duloxetine (30 mg with food, 60 mg with food, 30 mg without food, and 60 mg without food) in Korean patients with…
- Trial name
- NCT00960986
- Testing
- Duloxetine hydrochloride
- Where
- 7 sites in South Korea
- Volunteers
- 249 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
- Trial name
- MOONSTONE (NCT00320268)
- Testing
- Quetiapine fumarate
- Where
- 37 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
To evaluate the long-term safety and tolerability of flexible doses, 15 and 20 mg/day, of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD)
- Trial name
- NCT01323478
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 71 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder (MDD
A Study of ONO-1110 in Patients With Major Depressive Disorder
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Major Depressive Disorder
- Trial name
- NCT06792136
- Testing
- ONO-1110
- Where
- 29 sites in Japan
- Volunteers
- 103 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Major Depressive Disorder(MDD)
Efficacy of Clinical Application of Transcranial Low Intensity Focused Ultrasonic Stimulation for Patients With Major Deperessive Disorder - Exploratory Clinical Trial
The non-invasive type ultrasonography system is applied to patients with major depressive disorder to evaluate their effectiveness and safety.
- Trial name
- NCT04405791
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Gangnam Severance Hospital
Depression, Insomnia
Cognitive Behavioral Therapy for Insomnia with RTMS
Depression and insomnia occur together in a substantial number of patients. Transcranial magnetic stimulation (TMS) is an effective treatment for depression, but does not help insomnia symptoms in depressed patients.
- Trial name
- NCT04258618
- Testing
- CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS, Repetitive Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Medical University of South Carolina
Major Depressive Episode, Major Depressive Disorder
Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety
This trial compares intermittent theta-burst stimulation (iTBS) to low frequency repetitive transcranial magnetic stimulation (LFR) in regards to depression and anxiety outcomes in 100 patients with treatment resistant depression…
- Trial name
- PORT (NCT05028738)
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Major Depressive Disorders
Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
Primary objective : To demonstrate the antidepressant efficacy on the Hamilton Depression Rating Scale of SR58611A 700mg/day compared with placebo in the treatment of patients with a recurrent major depressive episode.
- Trial name
- NCT00825058
- Testing
- amibegron (SR58611A), paroxetine
- Where
- 8 sites in Bulgaria, Croatia and 6 more
- Volunteers
- 317 people
- Sponsor
- Sanofi
Major Depressive Disorder
Repurposing of Dextromethorphan as an Adjunct Therapy in Patients With Major Depressive Disorder
Therapeutic latency, lack of efficacy, and adverse drug reactions are the major concerns in current antidepressant therapies. One-third of the patients with major depressive disorder do not respond to conventional antidepressants…
- Trial name
- NCT05181527
- Testing
- Selective Serotonin Reuptake Inhibitors, Dextromethorphan
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Depression
Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT
The purpose of this study is to see whether the medication mifepristone is an effective and tolerable treatment for increasing the clinical effectiveness of electroconvulsive therapy (ECT) and protecting cognitive function during…
- Trial name
- NCT00285818
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Major Depression
Prediction of SSRI Treatment in Major Depression.
This project will combine the data collected from EEG, Eye tracking, structural and functional MRI scans and neuropsychological performance from patients with major depression receiving SSRI treatment.
- Trial name
- NCT03670823
- Testing
- SIEMENS PRISMA MRI
- Where
- Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- ElMindA Ltd
Resistant Depression, Treatment
TReAtment With CombinedExercise in Patients With Resistant Major Depression
Major depressive disorder is one of the most prevalent and disabling mental disorders worldwide. Forty percent of people with major depressive disorder are in moderate remission, with the remainder meeting the criteria for…
- Trial name
- TRACE-RMD (NCT05136027)
- Testing
- Combined training
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- University of the Basque Country (UPV/EHU)
Depressive Disorder, Treatment-Resistant
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
This study evaluated the efficacy and safety of the compound MIJ821 compared to placebo in patients aged from 18 to 65 years diagnosed with treatment-resistant depression. The study was conducted in the US and in Europe (Spain).
- Trial name
- NCT03756129
- Testing
- MIJ821, Ketamine
- Where
- 12 sites in United States, Spain
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Periodontitis, Depression
Impact of Periodontal Therapy on Mental Health Parameters
Objectives: Primary: To determine the efficacy of periodontal treatment on mental health outcomes in patients with major depression and periodontitis.
- Trial name
- LeakBrainRCT (NCT06036472)
- Testing
- Standard periodontal therapy (steps 1 & 2), supragingival debridement with anesthesia (step 1)
- Where
- 2 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Universidad Complutense de Madrid
Depressive Disorder, Major
Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder
The main objective was to compare the differences of PSG parameters and plasma melatonin levels before and after treatment with escitalopram for 8 weeks.
- Trial name
- NCT04013464
- Testing
- Escitalopram
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Peking University Sixth Hospital
Schizophrenia, Bipolar Disorder
Dental Status of Patients With Severe Mental Illness
The investigators aim to assess the dental status of psychiatric patients suffering from severe mental illness (schizophrenia, bipolar disorder, ptsd, resistant depression).
- Conditions
- Schizophrenia, Bipolar Disorder, PTSD, Depression
- Trial name
- SMI-DENTAL (NCT01315509)
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Hadassah Medical Organization
Major Depressive Disorder
A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients
Study F1J-US-HMFS comprises two identical multicenter, 9-month, randomized, placebo-controlled, double-blind, trials (HMFSa and HMFSb).
- Trial name
- NCT00536471
- Testing
- Duloxetine hydrochloride
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 776 people
- Sponsor
- Eli Lilly and Company